Takeda teams with GammaDelta to develop novel cell therapies

By Gareth Macdonald contact

- Last updated on GMT

(Source Takeda)
(Source Takeda)

Related tags: Protein, Cancer

Takeda has teamed up with GammaDelta Therapeutics to develop novel T-cell-based therapies in a deal that includes an option to buy the year-old UK biotech.

As the name suggests, GammaDelta is focused on using gamma delta T-cells to treat disease. Unlike alpha beta and B cells that bind specific foreign receptors, alpha delta cells respond to a range of chemical signals released by stressed cells.

The idea is that gamma delta-based cell therapies will be able to recognize a wider variety of tumours. In addition, because gamma delta cells do not target specific receptors, cancerous cells cannot evade detection by modifying expression patterns.

GammaDelta did not respond to a request for additional information. On its website the firm claims it is able to isolate gamma delta cells, culture them and turn into therapies.

$100m R&D deal

Takeda – and GammaDelta’s venture capital backer Abingworth LLC – have committed $100m (€92m) to the partnership, some of which will be used to fund R&D.

Daniel Curran, head of Takeda’s Center for External Innovation, said: “This collaboration is another example of our strategy to invest in highly innovative areas of science and we’re pleased to collaborate with the experienced team at GammaDelta​.”

The deal – which gives Takeda an equity stake in GammaDelta as well as the option to buy – is similar to the $125m agreement it struck with T cell developer Maverick Therapeutics Inc. in January.

The option to acquire is in keeping with its $35m agreement with PvP Biologics, also signed in January.

Related news

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Related suppliers

Follow us


View more